TWST · Twist Bioscience Corp · Investor Relations

Antibody characterization data generated by Twist supports TuneLab AI models designed to accelerate antibody discovery SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 16, 2026-- Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced an agreement

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 9, 2026-- Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience, will participate

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 4, 2026-- Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the pricing of an upsized underwritten public offering of 3,125,000 shares of its common stock at a price to the public of

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 4, 2026-- Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the commencement of an underwritten public offering of $250.0 million of shares of its common stock.

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 4, 2026-- As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value biotech company, today announced that a total of 44,434 restricted stock units

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 3, 2026-- Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the third quarter fiscal 2026 ended June 30, 2026.

Company to host conference call at 8:00 AM ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 15, 2026-- Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it will issue its financial results for the fiscal 2026 third quarter ended June

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 27, 2026-- Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience and Adam Laponis, CFO of Twist Bioscience will present at the

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 5, 2026-- As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value biotech company, today announced that a total of 115,279 equity awards, consisting of

Synthesis of structurally complex and highly-engineered protein sequences to enable acceptance of approximately 99.5% of clonal gene orders and 99.9% of all DNA products Complex synthesis capabilities to support further advancement of AI-enabled drug discovery and nucleic acid therapeutics SOUTH

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 4, 2026-- Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the second quarter fiscal 2026 ended March 31, 2026.

Company to host conference call at 8:00 AM ET Investor Day Scheduled for May 21, 2026 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 21, 2026-- Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it will issue its financial results for

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 18, 2026-- Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience, will participate

B-Body ® platform complements Twist’s antibody discovery offering enabling rapid, efficient and precise expression and discovery of complex bispecific antibody therapeutics Platform to power high-throughput characterization of bispecific antibodies to fuel AI-enabled and traditional drug discovery

Twist TrueAmp Library Preparation Kit with in-house developed enzymes including new Twist TrueAmp Polymerase Twist PCR-Free WGS Library Preparation Kit designed to meet the needs of the growing whole genome sequencing market New kits compatible with additional Twist NGS Applications tools for

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 3, 2026-- As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value biotech company, today announced that a total of 114,869 equity awards, consisting of

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 2, 2026-- Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the first quarter fiscal 2026 ended December 31, 2025.